[1]刘 慧,钟娇影,刘 杰,等.糖尿病肾病患者血清miR-495-3p 和LncRNA NEAT1 表达水平及其与患者预后的相关性研究[J].现代检验医学杂志,2023,38(03):35-39.[doi:10.3969/j.issn.1671-7414.2023.03.007]
　LIU Hui,ZHONG Jiao-ying,LIU Jie,et al.Study on the Expression Levels of Serum miR-495-3p and LncRNA NEAT1 in Diabetic Nephropathy and Their Relationship with Prognosis of Patients[J].Journal of Modern Laboratory Medicine,2023,38(03):35-39.[doi:10.3969/j.issn.1671-7414.2023.03.007]
点击复制

糖尿病肾病患者血清miR-495-3p 和LncRNA NEAT1 表达水平及其与患者预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年03期
页码:
35-39
栏目:
论著
出版日期:
2023-05-15

文章信息/Info

Title:
Study on the Expression Levels of Serum miR-495-3p and LncRNA NEAT1 in Diabetic Nephropathy and Their Relationship with Prognosis of Patients
文章编号:
1671-7414（2023）03-035-05
作者:
刘 慧; 钟娇影; 刘 杰; 陈秀娟
（河北以岭医院肾病科，石家庄 050000）
Author(s):
LIU Hui;  ZHONG Jiao-ying;  LIU Jie;  CHEN Xiu-juan
（Department of Nephrology, Hebei Yiling Hospital, Shijiazhuang 050000, China）
关键词:
糖尿病肾病; 微小RNA-495-3p; 长链非编码RNA 核富集转录体1
分类号:
R587.2；R392.11
DOI:
10.3969/j.issn.1671-7414.2023.03.007
文献标志码:
A
摘要:
目的 研究血清微小RNA（micro RNA, miR）-495-3p，长链非编码RNA 核富集转录体1（LncRNA NEAT1）水平与糖尿病肾病（DN）患者预后的关系。方法 纳入河北以岭医院2019 年1 月～ 2021 年1 月期间116 例DN 患者作为DN 组，收集其临床资料，根据肾脏病理损伤程度分为I 级组、II 级组、III 级组和IV 级组；根据治疗后6 个月随访期间是否发展为终末期肾病分为预后良好组和预后不良组；另收集同期单纯2 型糖尿病（T2DM）患者102 例作为T2DM 组和健康体检者100 例作为对照组。采用实时荧光定量PCR（qRT-PCR）法检测血清miR-495-3p 和LncRNANEAT1 水平；采用受试者工作特征（ROC）曲线分析血清miR-495-3p 和LncRNA NEAT1 水平对DN患者预后的预测价值。结果 对照组、T2DM 组和DN 组血清miR-495-3p 水平（1.02±0.25，0.76±0.22，0.58±0.16）依次降低，LncRNANEAT1 水平（1.01±0.23，1.58±0.29，2.16±0.36）依次升高，差异均有统计学意义（F=117.238，391.506，均P ＜ 0.05）。DN 中T2DM 病程≥ 10 年，eGFR ≥ 60 ml/min/1.73 m2，FBG ≥ 8mmol/L，24 h 尿蛋白≥ 3 g/24 h 的血清miR-495-3p水平（0.52±0.14，0.52±0.15，0.50±0.16，0.49±0.15）低于T2DM病程＜ 10 年，eGFR＜ 60 ml/min/1.73 m2，FBG＜ 8mmol/L 和24 h 尿蛋白＜ 3 g/24 h（0.67±0.18，0.69±0.19，0.70±0.19，0.73±0.18）；而LncRNA NEAT1 水平（2.33±0.42，2.29±0.38，2.35±0.43，2.31±0.40）高于T2DM 病程＜ 10 年，eGFR ＜ 60 ml/min/1.73 m2，FBG ＜ 8mmol/L 和24 h尿蛋白＜ 3 g/24 h（1.90±0.31，1.92±0.33，1.88±0.31， 1.90±0.36），差异均有统计学意义（tmiR-495-3p=5.033，5.300，6.122，7.721，t LncRNA NEAT1=5.956，5.244，6.436，5.529，均P ＜ 0.05）。I 级组、II 级组、III 级组和IV 级组血清miR-495-3p 水平（0.74±0.19，0.61±0.16，0.50±0.08，0.39±0.06）依次降低，LncRNA NEAT1 水平（1.69±0.30，2.08±0.32，2.34±0.35，2.74±0.39）依次升高，差异有统计学意义（F=32.060，46.730，均P ＜ 0.05）。预后不良组血清miR-495-3p 水平（0.45±0.10）低于预后良好组（0.65±0.17），LncRNA NEAT1（2.53±0.47）水平高于预后良好组（1.97±0.36），差异有统计学意义（t=6.836，7.148，均P ＜ 0.05）。血清miR-495-3p，LncRNA NEAT1 水平单独及联合预测DN 患者预后不良的曲线下面积（AUC）分别为0.784（95%CI: 0.702 ～ 0.867），0.753（95%CI: 0.658 ～ 0.848）和0.834（95%CI:0.755 ～ 0.912），特异度分别为71.1%，86.8% 和77.6%，敏感度分别为62.5%，57.5% 和77.5%。结论 DN 患者血清miR-495-3p 低表达，LncRNA NEAT1 高表达，二者水平与DN 患者肾损伤及预后有关。
Abstract:
Objective To study the relationship between serum microRNA(miR)-495-3p, long non-coding RNA nuclearenriched abundant transcript 1 (LncRNA NEAT1) levels and the prognosis of patients with diabetic nephropathy (DN). Methods A total of 116 DN patients in Hebei Yiling Hospital from January 2019 to January 2021 were included as DN group, and their clinical data were collected. According to the degree of renal pathological injury, they were divided into grade I group, grade II group, grade III group and grade IV group, and according to whether they developed end-stage renal disease during the 6-month follow-up period after treatment, they were grouped into a good prognosis group and a poor prognosis group. Another 102 patients with simple type 2 diabetes mellitus (T2DM) were collected as the T2DM group, and 100 healthy subjects were collected as the control group. Serum miR-495-3p and LncRNA NEAT1 levels were detected by real-time quantitative PCR (qRT-PCR)， and receiver operating characteristic (ROC) curve was applied to analyze the predictive value of serum miR-495-3p and LncRNA NEAT1 levels on the prognosis of DN patients. Results The level of serum miR-495-3p (1.02±0.25,0.76±0.22, 0.58±0.16)in the control group, T2DM group and DN group decreased in turn, while the level of LncRNA NEAT1 (1.01±0.23, 1.58±0.29, 2.16±0.36) increased in turn, with statistically significant differences (F=117.238, 391.506, all P<0.05). In DN patients, the serum miR-495-3p levels （0.52 ± 0.14, 0.52 ± 0.15, 0.50 ± 0.16, 0.49 ± 0.15）of T2DM patients ≥ 10 years， eGFR ≥ 60 ml/min/1.73 m2，FBG ≥ 8 mmol/L and 24h urinary protein ≥ 3 g/24h were lower than those of T2DM patients<10 years，eGFR<60 ml/min/1.73 m2 ，FBG<8 mmol/L and 24h urinary protein<3g/24h （0.67±0.18，0.69±0.19，0.70±0.19， 0.73±0.18）, and level of LncRNA NEAT1 (2.33 ± 0.42, 2.29 ± 0.38, 2.35 ± 0.43, 2.31 ± 0.40) was higher than that of T2DM with course of disease<10 years, eGFR<60 ml/min/1.73 m2, FBG<8 mmol/L and 24h urine protein<3 g/24h （1.90±0.31， 1.92±0.33, 1.88±0.31, 1.90±0.36）, with differences were statistically significant （tmiR-495-3p=5.033，5.300，6.122，7.721， tLncRNA NEAT1=5.956, 5.244, 6.436, 5.529, all P ＜ 0.05）. Serum level of miR-495-3p (0.74±0.19, 0.61±0.16, 0.50±0.08, 0.39±0.06) in grade I，grade II，grade III and grade IV groups decreased in turn, while the level of LncRNA NEAT1 (1.69±0.30, 2.08±0.32, 2.34±0.35, 2.74±0.39) increased in turn, with differences were statistically significant (F=32.060, 46.730, all P<0.05). The level of serum miR-495-3p (0.45±0.10 ) in the poor prognosis group was lower than that in the good prognosis group（0.65±0.17）, and the level of LncRNA NEAT1 (2.53±0.47 ) was higher than that in the good prognosis group （1.97±0.36）, with differences were statistically significant (t=6.836,7.148, all P<0.05). The area under the curve (AUC) of serum miR-495-3p and LncRNA NEAT1 levels alone and in combination for predicting poor prognosis in DN patients was 0.784 (95%CI: 0.702 ～ 0.867), 0.753 (95%CI: 0.658 ～ 0.848) and 0.834 (95%CI: 0.755 ～ 0.912), respectively, the specificity was 71.1%, 86.8% and 77.6%, respectively, and the sensitivity was 62.5%, 57.5% and 77.5%, respectively. Conclusion Serum miR- 495-3p in DN patients was lowly expressed, and LncRNA NEAT1 was highly expressed, and the levels of both were related to renal injury and prognosis in DN patients.

参考文献/References:

[1] YU Dahai, WANG Zheng, ZHANG Xiaoxue, et al. Remnant cholesterol and cardiovascular mortality in patients with type 2 diabetes and incident diabetic nephropathy[J]. The Journal of Clinical Endocrinology and Metabolism, 2021, 106(12): 3546-3554.
[2] FAYED A, RABIEE A, EL-SAADANY O, et al. Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy in Egyptian patients with type 2 diabetes mellitus[J]. Saudi Journal of Kidney Diseases and Transplantation, 2021, 32(5): 1340-1347.
[3] THIPSAWAT S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature[J]. Diabetes & Vascular Disease Research,2021, 18(6): 14791641211058856.
[4] LI Guoqing, ZHANG Jun, LIU Dechen, et al. Identification of hub genes and potential ceRNA networks of diabetic nephropathy by weighted gene Coexpression network analysis[J]. Frontiers in Genetics,2021, 12: 767654.
[5] XIE Jiayong, CHEN Zhi, YAO Gang, et al. NUP160 knockdown inhibits the progression of diabetic nephropathy in vitro and in vivo[J]. Regen Ther, 2022,21: 87-95.
[6] 北京大学医学系糖尿病肾脏病专家共识协作组．糖 尿病肾脏病诊治专家共识[J]．中华医学杂志, 2020,100(4)：247-260． Peing University Department of Medicine Diabetic Nephrology Expert Consensus Collaboration Group. Expert consensus on diagnosis and treatment of diabetic nephropathy[J]. National Medical Journal of China,2020, 100(4): 247-260.
[7] 中国医师协会内分泌代谢科医师分会, 国家代谢性 疾病临床医学研究中心. 糖尿病分型诊断中国专家 共识[J]．中华糖尿病杂志, 2022, 14(2)：120-139. Chinese Endocrinologist Association, Chinese Medical Doctor Association, National Clinical Research Center for Metabolic Diseases . Classification of diabetes mellitus in China: an expert consensus statement [J]. Chinese Journal of Diabetes, 2022, 14(2): 120-139.
[8] ZHANG Dongsheng, HUANG Yang, GAO Jie, et al. Altered functional topological organization in type- 2 diabetes mellitus with and without microvascular complications[J]. Frontiers in Neuroscience, 2021, 15: 726350.
[9] QUAN K Y, YAP C G, JAHAN N K, et al. Review of early circulating biomolecules associated with diabetes nephropathy Ideal candidates for early biomarker array test for DN[J]. Diabetes Research and Clinical Practice,2021, 182: 109122.
[10] 沈伟兴, 汤佳瑾, 傅鹏．2 型糖尿病肾病患者外周血 micorRNA-155 水平与肾小球滤过率的相关性研究 [J]. 现代检验医学杂志, 2022, 37(1)：12-16, 37. SHEN Weixing, TANG Jiajin, FU Peng. Correlation between microRNA-155 level in peripheral blood and glomerular filtration rate in patients with type 2 diabetic nephropathy[J]. Journal of Modern Laboratory Medicine, 2022, 37(1): 12-16, 37.
[11] ZHAO Yunyun, YAN Guanchi, MI Jia, et al. The impact of lncRNA on diabetic kidney disease: systematic review and in silico analyses[J]. Computational Intelligence and Neuroscience, 2022, 2022: 8400106.
[12] WU Xu, FAN Deyong, CHEN Bo. LncRNA NEAT1 accelerates the proliferation, oxidative stress, inflammation, and fibrosis and suppresses the apoptosis through the miR-423-5p/GLIPR2 axis in diabetic nephropathy[J]. Journal of Cardiovascular Pharmacology, 2022, 79(3): 342-354.
[13] LI Yameng, XU Yukun, HOU Yawei, et al. Construction and bioinformatics analysis of the miRNA-mRNA regulatory network in diabetic nephropathy[J]. Journal of Healthcare Engineering, 2021, 2021: 8161701.
[14] HE Yan, SUN Yuanzhu, PENG Jun. Circ_0114428 regulates Sepsis-Induced kidney injury by targeting the miR-495-3p/CRBN axis[J]. Inflammation, 2021, 44(4): 1464-1477.
[15] XU Lei, CAO Hongxia, XU Peng, et al. Circ_0114427 promotes LPS-induced septic acute kidney injury by modulating miR-495-3p/TRAF6 through the NF-κB pathway[J]. Autoimmunity, 2022, 55(1): 52-64.
[16] SHAN Guang, HUANG Ting, TANG Tian. Long noncoding RNA MEG8 induced by PLAG1 promotes clear cell renal cell carcinoma through the miR-495-3p/ G3BP1 axis[J]. Pathology Research and Practice, 2022,229: 153734.
[17] FAN Wei, LI Xudong, XU Xiangjun, et al. Effects of high-flux dialysis combined with hemoperfusion on serum GRP78 and miR-495-3p in renal failure patients[J]. BioMed Research International, 2021,2021: 9591177.
[18] WEI Xiang, XU Shan, CHEN Liang. LncRNA neat1/ miR-298-5p/Srpk1 contributes to Sevoflurane-Induced neurotoxicity[J]. Neurochemical Research, 2021,46(12): 3356-3364.
[19] GONG Yi, DONG Xiao, XU Jianjun, et al. LncRNA NEAT1 knockdown ameliorates LPS-induced human kidney injury by mediating the miR-330-5p/FOXO3 axis[J]. International Urology and Nephrology, 2022,54(10): 2683-2694.
[20] 韩辉, 林书典, 陈道军, 等．血清微小核糖核酸-133b 水平与老年糖尿病肾病患者肾脏损伤及预后的相关 性[J]. 中华老年多器官疾病杂志, 2018, 17(6)：420- 424． HAN Hui, LIN Shudian, CHEN Daojun, et al. Correlation between serum miR-133b level and renal injury and prognosis in the elderly with diabetic nephropathy[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2018, 17(6): 420-424.

相似文献/References:

[1]张春雷,曾学辉,李忠新,等.尿KIM-1和NGAL在糖尿病肾病早期诊断中的应用[J].现代检验医学杂志,2015,30(01):52.[doi:10.3969/j.issn.1671-7414.2015.01.014]
　ZHANG Chun-lei,ZENG Xue-hui,LI Zhong-xin,et al.Value of Urinary KIM-1 and NGAL in Predicting the Early Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2015,30(03):52.[doi:10.3969/j.issn.1671-7414.2015.01.014]
[2]阿地拉·阿布里孜,王 霞,屈晓威.联合检测视黄醇结合蛋白和膜联蛋白A2水平对糖尿病肾病早期诊断的意义[J].现代检验医学杂志,2016,31(05):118.[doi:10.3969/j.issn.1671-7414.2016.05.033]
　ADILA·Abulizi,WANG Xia,QU Xiao-wei.Significance of Combined Detection of Serum Retinol-Binding Protein and AnnexinA2 in Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2016,31(03):118.[doi:10.3969/j.issn.1671-7414.2016.05.033]
[3]于菲菲,庞白冰,杨 华,等.单纯性2型糖尿病与糖尿病肾病患者尿液中α1-微球蛋白和激肽原1的表达分析[J].现代检验医学杂志,2017,32(05):94.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　YU Fei-fei,PANG Bai-bing,YANG Hua,et al.Expression Analysis of α1-Microglobulin,Kininogen1 in Urine of Simple Type 2 Diabetes and Diabetic Nephropathy Patients[J].Journal of Modern Laboratory Medicine,2017,32(03):94.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[4]吴忠璟,陈亚凤,高芳虹.糖尿病肾病患者血清miR-135b水平检测与疾病预后的相关性研究[J].现代检验医学杂志,2018,33(03):88.[doi:10.3969/j.issn.1671-7414.2018.03.022]
　WU Zhong-jing,CHEN Ya-feng,GAO Fang-hong.Correlation between Serum miR-135b Level and Prognosis in Patients with Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2018,33(03):88.[doi:10.3969/j.issn.1671-7414.2018.03.022]
[5]杨翠伶.血清miR-150-5p和miR-155-5检测对老年糖尿病肾病的诊断价值[J].现代检验医学杂志,2018,33(05):74.[doi:10.3969/j.issn.1671-7414.2018.05.020]
　YANG Cui-ling.Diagnostic Value of Serum miR-150-5p and miR-155-5 Detection in Elderly Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2018,33(03):74.[doi:10.3969/j.issn.1671-7414.2018.05.020]
[6]谭志敏,张 燕,滕雅娟,等.糖尿病肾病患者血清甲状腺激素水平变化及其与亚临床甲状腺功能减退的相关性[J].现代检验医学杂志,2018,33(06):95.[doi:10.3969/j.issn.1671-7414.2018.06.025]
　TAN Zhi-min,ZHANG Yan,TENG Ya-juan,et al.Correlation between Serum Thyroid Hormone Levels in Patients with Diabetic Kidney Disease and Subclinical Hypothyroidism[J].Journal of Modern Laboratory Medicine,2018,33(03):95.[doi:10.3969/j.issn.1671-7414.2018.06.025]
[7]张求霞a,汪隆海a,昌国庆a,等.尿液6种蛋白与CysC水平检测对糖尿病肾病的诊断价值[J].现代检验医学杂志,2019,34(01):67.[doi:10.3969/j.issn.1671-7414.2019.01.017]
　ZHANG Qiu-xiaa,WANG Long-haia,CHANG Guo-qing a,et al.Clinical Value of Detection of 6 Proteins and Cystatin C in Urine for Early Diagnosis of Diabetic Kidney Disease[J].Journal of Modern Laboratory Medicine,2019,34(03):67.[doi:10.3969/j.issn.1671-7414.2019.01.017]
[8]张曙晴,张骆军,李洪彬,等.血液小而密低密度脂蛋白胆固醇、抗凝血酶Ⅲ水平及血小板参数检测在2型糖尿病肾病中的应用价值研究[J].现代检验医学杂志,2021,36(02):70.[doi:doi:10.3969/j.issn.1671-7414.2021.02.017]
　ZHANG Shu-qing,ZHANG Luo-jun,LI Hong-bin,et al.Study on the Application Value of Detecting Small Dense Low-density Lipoprotein Cholesterol, Antithrombin-Ⅲ Levels and Platelet Parameter in the Patients with Type-2 Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2021,36(03):70.[doi:doi:10.3969/j.issn.1671-7414.2021.02.017]
[9]闫海燕,杨云秀,杨云华,等.老年糖尿病肾病患者血清SP-D水平表达及其基因多态性与并发肺部感染的相关性研究[J].现代检验医学杂志,2021,36(04):21.[doi:10.3969/j.issn.1671-7414.2021.04.005]
　YAN Hai-yan,YANG Yun-xiu,YANG Yun-hua,et al.Research on the Relationship between Serum SP-D Level, Gene Olymorphismand Pulmonary Infection in Elderly Patients with Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2021,36(03):21.[doi:10.3969/j.issn.1671-7414.2021.04.005]
[10]祁桠楠a,胡江伟b,武　亮c,等.血清TLR-3，miR-181b及URBP联合检测在糖尿病肾病诊断及预后判断的价值研究[J].现代检验医学杂志,2022,37(02):37.[doi:10.3969/j.issn.1671-7414.2022.02.008]
　QI Ya-nana,HU Jiang-weib,WU Liangc,et al.Value of Combined Detection of Serum TLR-3, miR-181b and URBP in Diagnosis and Prognosis of Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2022,37(03):37.[doi:10.3969/j.issn.1671-7414.2022.02.008]

备注/Memo

备注/Memo:
基金项目：河北省中医药管理局科研计划项目（编号：2021190）。
作者简介：刘慧（1988-），女，硕士研究生，主治中医师，从事膜性肾病、糖尿病肾病研究，E-mail：hukzxm@163.com。
通讯作者：陈秀娟（1981-），女，本科，副主任中医师，从事糖尿病肾病、慢性肾功能衰竭研究，E-mail：147241589@qq.com。
更新日期/Last Update: 2023-05-15